Two practice parameters from the Joint Task Force for Practice Parameters offer evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis in pediatric and adult patients.
The FDA has approved dupilumab (Dupixent, Regeneron) as an add-on maintenance treatment of patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
Dupilumab is generally well tolerated and improves health-related quality of life associated with rhinoconjunctivitis in patients with asthma and comorbid allergic rhinitis.
